Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone

Clinical Neuropharmacology

Volumn 32, Issue 5, 2009, Pages 250-253

  Kim, Jong Hoon ^a   Kim, Min Jung ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Akathisia; Extrapyramidal side effect; Risperidone; Schizophrenia; Subjective well being

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; WELLBEING;

ADULT; AFFECT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 70349792615     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181a5d08c     Document Type: Article

References (46)

1. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006;67:1690 Y1697.
2. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(suppl 3):133 Y138.
3. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79 Y 88.
4. Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002;56:37Y 46.
5. Kim JH, Kim SY, Ahn YM, et al. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:301-305.
6. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002;162:3 Y10.
7. Ritsner M, Perelroyzen G, Ilan H, et al. Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004;24:245-254.
8. Awad AG, Voruganti LN, Heslegrave RJ, et al. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996;11(suppl 2):55-59.
9. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004;18(suppl 2):5-17.
10. Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res 1997;6:21-26.
11. Voruganti LN, Heslegrave RJ, Awad AG. Quality of life measurement during antipsychotic drug therapy of schizophrenia. J Psychiatry Neurosci 1997;22:267-274.
12. Kemmler G, Meise U, Tasser A, et al. Subjective quality of life of schizophrenic patients. Effect of treatment setting, psychopathology and extrapyramidal motor drug effects. Psychiatr Prax 1999;26:9-15.
13. Ritsner M, Ponizovsky A, Endicott J, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002;12:31-38.
14. Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology, and tardive dyskinesia. Acta Psychiatr Scand 1996;94:118-124.
15. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996; 93:381-388.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press; 1994.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of HEW Publication; 1976:217-222.
18. Owens DGC. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge, UK: Cambridge University Press; 1999.
19. de Haan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the Subjective Well-being Under Neuroleptics Scale and the Subjective Deficit Syndrome Scale. Psychopharmacology 2002;162:24-28.
20. Naber D, Riedel M, Klimke A, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005;111:106 Y115.
21. Karow A, Moritz S, Lambert M, et al. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005;38:320-Y326.
22. Lambert M, Schimmelmann BG, et al. Long-term patterns of subjective well-being in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years. Schizophr Res 2008; doi:10.1016/j.schres.2008.08.035.
23. Yoon JS, Kook SH, Lee HY, et al. The development of a Korean modification of the scale to measure Subjective Well-being Under Neuroleptic Treatment (SWN). J Korean Neuropsychiatr Assoc 2000;39:987Y-998.
24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
25. Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995;166:650-Y653.
26. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000;43:135-145.
27. Mutsatsa SH, Joyce EM, Hutton SB, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand 2003;108:439-446.
28. Barbui C, Nosè M, Bindman J, et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 2005; 25:521-526.
29. Inada T. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage. Tokyo, Japan: Seiwa Shoten Publishers; 1996.
30. Kim JH, Jung HY, Kang UG, et al. Metric characteristics of the DIEPSS: a practical combined rating scale for drug-induced movement disorders. Mov Disord 2002;17:1354-Y1359.
31. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 2002;57:227-238.
32. Inada T, Beasley Jr CM, Tanaka Y, et al. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 2003;18:39-48.
33. Kim JH, Cho SY, Byun HJ, et al. Multidimensional sensory phenomena in antipsychotic-induced akathisia. J Clin Psychopharmacol 2004; 24:618-623.
34. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004;65:932-939.
35. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24.
36. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45.
37. Hansen LK. AkathisiaVseen from the patients' perspective. J Psychopharmacol 2008;22:572-573.
38. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006;14:152-164.
39. Miodownik C, Lerner V, Statsenko N, et al. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clin Neuropharmacol 2006;29:68-72.
40. Lerner V, Bergman J, Statsenko N, et al. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2004;65:1550-Y1554.
41. The NIDS Working Group. Neuroleptic induced deficit syndrome (NIDS). J Clin Psychiatry 1993;54:494-500.
42. Voruganti LP, Awad AG. Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatr Scand Suppl 2005;427:22-28.
43. Mizrahi R, Rusjan P, Agid O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 2007; 164:630-Y637.
44. Fitzgerald PB, Williams CL, Corteling N, et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand 2001;103:387-392.
45. Trauer T, Duckmanton RA, Chiu E. A study of the quality of life of the severely mentally ill. Int J Soc Psychiatry 1998;44:79-91.
46. Wehmeier PM, Kluge M, Schacht A, et al. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res 2007;91:178-Y186.